Low-dose naltrexone is a repurposed prescription approach studied for intermittent opioid-receptor blockade, opioid-growth-factor signaling, immune modulation and treatment sensitization.
Share your diagnosis, current treatment and the questions you want the clinical team to consider.
Tell us what you are facing and what you hope to understand. The team will follow up personally.
At Sunridge, LDN is considered by dose, timing, opioid use, symptom goals and cancer-treatment context. The published cancer literature is narrower than for many nutrients, so this page focuses on the directly relevant positive studies.
Naltrexone with propranolol reduced breast-tumor growth, increased growth arrest and apoptotic proteins and shifted immune-environment signaling.
Naltrexone reduced established mammary-tumor volume in the reported model, with regression observed most often in hormone-receptor-positive tumors.
LDN reduced colorectal-tumor size while increasing M1-like macrophages and activating Bax, caspase and PARP-associated apoptosis.
Intermittent LDN exposure changed cell-cycle and immune genes and increased subsequent oxaliplatin-associated cell killing.
Daily intermittent opioid-receptor blockade delayed HT-29 tumor appearance and markedly retarded tumorigenicity in the reported model.
This review summarizes the proposed relevance of lower-dose naltrexone schedules to cancer biology and clinical research.
A recent review organizes LDN research involving the OGF–OGFr axis, immune signaling and potential combinations with chemotherapy and immunotherapy.
Brief receptor blockade reduced proliferation through the OGF–OGFr axis in ovarian, pancreatic, colorectal and squamous-carcinoma models.
A systematic review summarized tumor size, latency, survival, progression and cell-growth findings from clinical, animal and cell research.
LDN and opioid growth factor markedly reduced ovarian tumor nodule number and weight through proliferation and angiogenesis effects.
LDN reduced ovarian-cancer DNA synthesis and angiogenesis, slowed progression and enhanced the inhibitory effect of cisplatin.
Our Patient Care Team can help you begin a conversation about your diagnosis, current oncology plan, goals, medicines and integrative options used at Sunridge.
14200 N Northsight Blvd #160
Scottsdale, Arizona 85260
Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM
Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.
This introductory call is not a medical consultation and does not establish a physician-patient relationship.
